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ABSTRACT 
Diabetic cardiomyopathy is associated with increased oxidative stress and vascular 
endothelial dysfunction, that lead to coronary microangiopathy.  We tested 
whether statin-induced redox imbalance improvements could ameliorate diabetic 
cardiomyopathy and improve coronary microvasculature in streptozotocin-induced 
diabetes (DM).  Fluvastatin (10 mg/kg/day) or vehicle was orally administered for 
12 weeks to rats with or without DM.  Myocardial oxidative stress was assessed by 
NADPH oxidase subunit p22phox and gp91phox mRNA expression and myocardial 
8-iso-prostaglandin F2α (PGF2α) levels.  Myocardial vascular densities were 
assessed using anti-CD31 and anti-α smooth muscle actin (SMA) antibodies.  
Fluvastatin did not affect blood pressure or plasma cholesterol, but attenuated 
increased left ventricular (LV) minimum pressure and ameliorated LV systolic 
dysfunction in DM rats compared to vehicle (LVdP/dt, 8.9±1.8 vs. 5.4±1.0 ×103 
mmHg/s, p<0.05).  Myocardial oxidative stress increased in DM, but fluvastatin 
significantly reduced p22phox and gp91phox mRNA expression and myocardial PGF2α 
levels.  Fluvastatin enhanced myocardial endothelial NO synthase (eNOS) protein 
levels and increased eNOS, vascular endothelial growth factor, and 
hypoxia-inducible factor-1α mRNA expression.  CD31-positive cell densities were 
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lower in DM rats than in non-DM rats (28.4±13.2 vs. 48.6±4.3/field, p<0.05) and 
fluvastatin restored the number (57.8±18.3/field), although there were no 
significant differences in SMA-positive cell densities between groups.  Fluvastatin 
did not affect cardiac function, oxidative stress, or vessel densities in non-DM rats.  
These results suggest that beneficial effects of fluvastatin on diabetic 
cardiomyopathy might result, at least in part, from improving coronary 
microvasculature through reduction in myocardial oxidative stress and angiogenic 
factor up-regulation.  
 
Keywords 




 Patients with diabetes are often associated with reduced cardiac function 
despite the absence of coronary atherosclerotic disease, i.e., diabetic cardiomyopathy.  
Oxidative stress in diabetes plays a key role in the pathogenesis of diabetic 
cardiomyopathy (1, 2).  Hyperglycemia can stimulate the production of reactive 
oxygen species (ROS) from a variety of sources (3-6), and affect cardiac and 
endothelial function.  Clinical studies have demonstrated consistent abnormalities 
in the coronary flow reserve of patients with diabetes in the absence of epicardial 
coronary artery disease (7-9), while animal studies have shown that hearts in the 
presence of diabetes are associated with an impaired angiogenic capacity and 
reduced microvessel densities (10, 11).  Therefore, therapeutic interventions that 
aim to reduce oxidative stress and/or stimulate angiogenesis could inhibit the 
progression of diabetic cardiomyopathy. 
 Statins, a class of drugs used to lower blood cholesterol by inhibiting 
biosynthetic enzymes in the liver, effectively reduce the risk of cardiovascular 
events in patients with diabetes (12, 13).  The cardioprotective effects of statins, 
independent of their lipid-lowering-effect, could result primarily from increased NO 
bioavailability through the activation of endothelial NO synthase (eNOS) and 
enhancement of eNOS mRNA stability (14, 15).  Statin-induced eNOS increases 
and oxidative stress reductions inhibit intramyocardial inflammation (13, 16).  
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Moreover, statins mobilize endothelial progenitor cells from the bone marrow, while 
NO is a stimulator of angiogenesis (17).  Therefore, the purpose of the present 
study was to investigate whether fluvastatin, which has a powerful antioxidative 
effect (18), could inhibit the progression of diabetic cardiomyopathy by reducing 
myocardial oxidative stress and its proangiogenic action.  
 
MATERIALS AND METHODS 
This study proceeded in accordance with the University of Toyama 
guidelines for animal experiments. 
Experimental animals 
 Diabetes was induced in male 10-week-old Wistar rats by an 
intraperitoneal injection of 65 mg/kg of streptozotocin (STZ).  Control rats without 
diabetes were not injected with STZ.  The rats with glucose levels of > 300 mg/dL 
one week after the STZ injection were considered to have diabetes mellitus (DM) 
and were used in the following experiments.  Starting 2 weeks after the STZ 
injection, fluvastatin (10 mg/kg/day) was orally administered to the rats by gavage 
for 12 weeks.  Standard rat chow and tap water were provided ad libitum 









Echocardiographic and hemodynamic studies 
Transthoracic echocardiography was performed using an ultrasonography  
system equipped with a 7.5-MHz transducer (SONOLAYER SSA-260A, Toshiba, 
Tokyo, Japan) at the end of the study.  Left ventricular end-diastolic (LVDd) and 
left ventricular end-systolic (LVDs) diameters were determined under light 
anesthesia with sodium pentobarbital (15 mg/kg, i.p.).  After the echocardiographic 
study, a 2F micromanometer-tipped catheter was introduced through the right 
carotid artery and advanced to the left ventricle (LV) to determine LV systolic 
pressure (LVSP), minimum pressure, and maximal and minimal rates of LV 
pressure changes (LV dP/dtmax and LV dP/dtmin, respectively). 
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Quantitative real-time reverse-transcriptase polymerase chain reaction (PCR) 
The procedures for quantitative real-time reverse transcription PCR were 
described previously (19).  Briefly, total RNA extracted from 100 mg of LV tissue 
using Isogen (Nippon Gene, Tokyo, Japan) was digested with DNase (Takara Bio, 
Shiga, Japan) to eliminate genomic DNA contamination.   RNA samples were 
reverse transcribed with oligo (dT) primers using an RNA PCR kit (Takara Bio, 
Shiga, Japan).  Quantitative PCR analysis proceeded using a sequence detector 
(Mx3000P; Agilent Technologies, Santa Clara, CA, USA) in a total volume of 20 μL 
containing 1 μL of cDNA, 10 μL of reagent (Brilliant II Fast QPCR MasterMix; 
Agilent Technologies), 8 μL of diethylpyrocarbonate-treated water and 1 μL of 
primer and TaqMan probe sets (Applied Biosystems, CA, USA) specific for cDNAs 
encoding glyceraldehyde-3-phsosphate dehydrogenase (GAPDH), vascular 
endothelial growth factor A (VEGF), hypoxia-inducible factor-1α (HIF-1α) , nitric 
oxide synthase 3 endothelial cell (eNOS), cytochrome b-245 alpha polypeptide (p22), 
cytochrome b-245 beta polypeptide (gp91), and transforming growth factor beta 1 
(TGF-β1).  The PCR program comprised 40 cycles of denaturation at 95°C for 1 min, 
primer annealing at 40°C for 5 sec, and extension at 60°C for 20 sec. 
Immunoblotting 
Myocardial proteins were immunoblotted to determine rat eNOS protein 
levels, as described previously (19).  Tissue samples (20 μg of protein) were 
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resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 5 -15% 
gels (Ready Gel J; Bio-Rad Laboratories, Tokyo, Japan) and the separated proteins 
were transferred to a polyvinylidene difluoride membrane (Immun-Blot PVDF 
Membrane for Protein Blotting [0.2 μm]; Bio-Rad, Tokyo, Japan).  The membrane 
was incubated at room temperature for 1 hour with 5% skim milk and 0.1% 
Tween-20 in Tris-buffered saline and then overnight with rabbit polyclonal 
antibodies to eNOS (eNOS antibody; Cell Signalling Technologies, Beverly, MA, 
USA) at a 1:1000 dilution in the same solution.  The membrane was washed and 
incubated for 1 hour with a 1:1000 dilution of horseradish peroxidase-conjugated 
goat antibodies to rabbit IgG (anti-rabbit IgG HRP-linked antibody; Cell Signalling 
Technologies, Beverly, MA, USA).  The intensity of the eNOS bands was quantified 
using densitometry (LAS-4000; Fujifilm, Tokyo, Japan). 
Cardiac PGF2α levels 
The procedures for the determining of cardiac PGF2α were described 
previously (20).  Briefly, LV tissues were disrupted in a Polytron Homogenizer with 
50 mM HCl and the homogenate was centrifuged for 5 min.  The supernatant was 
extracted with ethyl acetate by centrifugation at 3,000 rpm for 5 min and the 
resulting organic layer was evaporated under a nitrogen stream.  The residue was 
dissolved in a mixture (50 μL) of acetonitrile and ethanol, and 1 mM HCl (2.5 mL) 
was then added.  Tissue extract was applied to Empore Disk Cartridges 
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pre-conditioned with methanol and 1 mM HCl.  The cartridges were washed with 1 
mM HCl followed by heptane.  We eluted PGF2α with ethyl acetate containing 1% 
methanol, and evaporated the eluate under a steam of nitrogen.  The residue was 
dissolved in 0.05% formic acid and acetonitrile, while the PGF2α level was 
determined using high performance liquid chromatography–electrospray 
ionization–mass spectrometry (API 4000™ LC/MS/MS; Applied Biosystems) (21).  
In the present study, we determined PGF2α levels in rats with DM but not in rats 
without DM, because the PGF2α level in rats without DM was below the detection 
limit (0.1 ng/g tissue) in our previous study (20). 
Histology 
The LV was cut into transverse slices, fixed in 10% formaldehyde, 
embedded in paraffin, and cut into 5-μm-thick sections for staining with Sirius Red 
to determine the fibrosis area.  Using an image analyzer (MetaMorph Image 
Analysis offline version 7.1.1.0), 4 fields at the level of the papillary muscle were 
randomly chosen at a magnification of ×400.  The fibrosis area was determined by 
an investigator who was unaware of the experimental groups. 
Immunohistochemical analysis 
Portions of the transversely cut LV specimens were immunohistochemically 
examined to determine coronary arteriolar and capillary densities.  Vascular 
smooth muscle and endothelial cells were detected by overnight incubation with 
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antibodies to α-smooth muscle actin (α-SMA M0851; Dako, Tokyo, Japan) and CD31 
(PECAM-1; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), respectively.  
The specimens were then incubated with biotinylated anti-rabbit IgG.  Arteriolar 
densities were determined from the number of α-SMA-positive microvessels with an 
internal diameter of <50 μm and ≥1 layer of smooth muscle cells at a magnification 
of ×400.  Capillary density was similarly determined from the number of 
CD31-positive vessels with an internal diameter of <10 μm at a magnification of 
×800.  Sixteen fields of the LV wall were randomly selected from each section and 
counted by an investigator who was unaware of the experimental groups 
Statistics 
 Results are expressed as means ± SD.  Differences among groups were 
tested using a one-way analysis of variance followed by the Bonferroni test for 




 Plasma blood glucose and triglyceride levels were markedly elevated in rats 
with DM.  Fluvastatin did not affect blood glucose or total cholesterol levels in rats 
with or without DM but attenuated the elevated triglyceride levels in rats with DM 
(Table 1).   
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 The body and heart weights of rats with DM were lower than those without 
DM, but the heart-to-body weight ratio was significantly greater in rats with DM 
(Table 2).  Rats with DM had elevated LV minimum pressure that was decreased 
by fluvastatin to the level seen in rats without DM.  Both maximum and minimum 
LVdP/dt values were reduced in rats with DM, but fluvastatin restored these values, 
although the significance of the improvement in minimum LVdP/dt was only 
borderline (p=0.089).  Echocardiographic assessment showed that LV fractional 
shortening was lower in rats with DM than in rats without DM, but was not 
significantly changed by fluvastatin. 
 
Table 1.  Blood glucose and plasma lipid levels 










BG (mg/dL) 168±73 170±66 414±41** 490±208** 
T-CHO (mg/dL) 82±9 74±12 104±21 92±21 
TG (mg/dL) 32±19 26±5 226±67** 129±73**,## 
NEFA (mEq/L) 0.57±0.10 0.67±0.19 1.19±0.31** 0.87±0.20 
Values are means ± SD.  ** p<0.01 vs. vehicle of non-diabetes mellitus (DM); ## 
p<0.01 vs. vehicle of DM.  BG indicates blood glucose; T-CHO, total cholesterol; TG, 
triglyceride; NEFA, non-esterified fatty acids. 
Table 2.  Hemodynamic data 
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BW (g) 467±14 450±26 242±60** 271±66** 
HW (mg) 1114±80 1061±116 869±170* 851±172* 
HW/BW (mg/g) 2.38±0.16 2.36±0.17 3.65±0.52** 3.19±0.42** 
HR (beats/min) 383±39 395±27 351±31 370±15 
Systolic LV P 
(mmHg) 
124±11 114±14 115±13 120±13 
    
Minimum LVP 
(mmHg) 
0±1 -2±2 7±8* -1±1## 
    
LV dP/dtmax 
 (x103 mmHg/s) 
9.69±2.23 9.56±1.64 5.42±1.03** 8.92±1.87# 
    
LV dP/dtmin 
 (x103 mmHg/s) 
-8.05±0.64 -7.84±1.70 -4.71±0.70** -6.52±1.48 
    
LVDd (mm) 5.0±0.71 5.19±0.35 5.69±0.51 5.84±0.49 
LVDs (mm) 1.67±0.56 1.96±0.42 2.86±0.45** 3.24±0.36** 
%FS 66.9±7.8 64.4±7.5 48.8±6.1** 44.2±5.2** 
Values are means ± SD.  * p<0.05 and ** p<0.01 vs. vehicle of non-diabetes 
mellitus (non-DM).  # p<0.05 and ## p<0.01 vs. vehicle of DM.  BW indicates body 
weight; HW, heart weight; HR, heart rate; LVP, left ventricular pressure; LV 
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dP/dtmax and LV dP/dtmin, peak rate of LVP rise and fall, respectively; LVDd and 
LVDs, LV end-diastolic and end-systolic dimension, respectively; FS, fractional 
shortening. 
 
Oxidative stress in the myocardial tissue 
 The expression of NADPH oxidase subunit p22phox and gp91phox in the 
myocardial tissue of rats with DM was significantly higher than that of rats without 
DM, while fluvastatin attenuated the upregulated expression of these subunits in 
rats with DM (Figure 1).  Similarly, cardiac levels of PGF2α were markedly low in 
fluvastatin-treated rats with DM, compared to rats with DM without fluvastatin 
treatment. 
Cardiac microvessel density and eNOS, VEGF and HIF-1α expression 
 The capillary density of LV assessed by CD31-positive cells was lower in 
rats with DM than in those without DM, but fluvastatin restored this value in rats 
with DM.  The arteriole densities were not significantly different among the 4 
groups (Figure 2).  Fluvastatin significantly increased both VEGF and HIF-1α  
expression in the myocardium of rats with and without DM.  In rats with DM, 
eNOS mRNA and its protein levels were also up-regulated by fluvastatin (Figure 3).  
The level of VEGF mRNA was correlated with eNOS (r=0.506, p<0.05) and HIF-1α  
(r=0.647, p<0.01) expression. 
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Cardiac fibrosis 
 Myocardial interstitial fibrosis was greater in rats with DM than in those 
without DM.  Fluvastatin inhibited DM-induced increases in interstitial fibrosis 
(Figure 4).  The up-regulated expression of TGF-β1 mRNA in rats with DM was 





Figure 1.  Left and middle panels, expression of myocardial NADPH oxidase 
subunit p22phox and gp91phox mRNA in rats without diabetes mellitus (non-DM rats) 
treated with vehicle (VE, n = 5) and fluvastatin (FL, n = 5) and in rats with DM 
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treated with VE (n = 5) and FL (n = 4).  Right panel, myocardial 8-iso-prostaglandin 
F2α (PGF2α) levels in rats with DM (DM rats) treated with VE (n = 5) and FL (n = 4).  
Values are means + SD.  ** p < 0.01 vs. VE of non-DM rats and ## p < 0.01 vs. VE of 
DM rats. 
 
Figure 2.  Representative photomicrographs of arterioles stained with α-smooth 
muscle actin (panel A) and capillaries with CD31 (panel B) in rats without diabetes 
mellitus (non-DM rats) treated with vehicle (VE) and fluvastatin (FL) and in rats 
with DM (DM rats) treated with VE and FL.  Panels C and D show a quantitative 
morphometric analysis of arterioles and capillaries, respectively, in non-DM rats 
treated with VE (n = 5) and FL (n = 4) and in DM rats treated with VE (n = 5) and FL 
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(n = 5).  Values are means + SD.  *p < 0.05 vs. VE of non-DM rats. # p < 0.05 vs. VE 




Figure 3.  Panels A, B, and C show vascular endothelial growth factor (VEGF), 
endothelial nitric oxide synthase (eNOS), and hypoxia-inducible factor (HIF)-1α 
gene expression in rats without diabetes mellitus (non-DM rats) treated with 
vehicle (VE, n = 5) and fluvastatin (FL, n = 5) and in rats with DM (DM rats) treated 
with VE (n = 5) and FL (n = 4).  Each mRNA level was normalized to the amount of 
GAPDH mRNA.  Panel D shows representative examples of western blots for eNOS 
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and a densitometric analysis of eNOS protein expression in non-DM rats treated 
with VE (n = 5) and FL (n = 5) and in DM rats treated with VE (n = 5) and FL (n = 4).  
Values are means + SD.  ** p < 0.01 vs. VE of non-DM rats. ## p < 0.01 vs. VE of DM 
rats. 
 
Figure 4. Panel A shows representative photomicrographs stained with Sirius Red 
in rats without diabetes mellitus (non-DM rats) treated with vehicle (VE) and 
fluvastatin (FL) and in rats with DM (DM rats) treated with VE and FL.  Panel B 
shows the quantitative morphometric analysis of fibrosis areas in non-DM rats 
treated with VE (n = 5) and FL (n = 5) and in DM rats treated with VE (n = 5) and FL 
(n = 4).  Panel C shows transforming growth factor-β1 (TGF-β1) gene expression in 
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non-DM rats treated with VE (n = 5) and FL (n = 5) and in DM rats treated with VE 
(n = 5) and FL (n = 4).  Values are means + SD.  * p < 0.05 and ** p < 0.01 vs. VE of 
non-DM rats. # p < 0.05 vs. VE of DM rats. 
 
DISCUSSION 
 The major findings of the present study are as follows.  First, a 3-month 
treatment with fluvastatin attenuated LV dysfunction in rats with STZ-induced DM.  
Second, fluvastatin suppressed the elevation of myocardial oxidative stress in rats 
with DM.  Finally, fluvastatin restored the reduced myocardial capillary density in 
rats with DM in association with the upregulation of myocardial eNOS, VEGF, and 
HIF-1α  expression.  These results suggest that the fluvastatin-induced LV 
dysfunction improvements might be a result, at least in part, of improved coronary 
vascularity in association with reduced myocardial oxidative stress in rats with DM. 
LV dysfunction in rats with DM 
 STZ-induced DM is a well established model for the study of diabetic 
cardiomyopathy (22).  The mechanisms involved in diabetic cardiomyopathy are 
not completely understood, but various factors might be involved in the progression 
of diabetic cardiomyopathy (23-25), including hyperglycemia (26), dyslipidemia (27), 
the production of inflammatory cytokines (28), increased oxidative stress (1, 2), and 
impaired coronary microcirculation (10, 11).   
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 Non-atherosclerotic cardiomyopathy independent of vascular complications 
occurs in roughly 30% of all patients with type I DM and presents with early 
diastolic abnormalities followed by a later decline in systolic and overt heart failure 
(29).  In the present study, LV dP/dt and LV fractional shortening were reduced, 
while minimum LV pressure was increased in rats with DM 12 weeks after the STZ 
injection, along with increases in myocardial oxidative stress and fibrosis but with 
myocardial capillary density reductions.  Fluvastatin attenuated these 
STZ-induced deteriorations except for LV fractional shortening, probably because 
LV fractional shortening is load-dependent and is determined only from changes in 
the minor axis of the LV chamber. 
Oxidative stress in DM rats 
 Studies have shown that oxidative stress is increased in both type I and 
type II DM (30, 31).  Hyperglycemia induces oxidative stress through several 
pathways (3, 5, 6), including enhanced aldose reductase activity (6), increased 
advanced glycation end products (3), and altered protein kinase C activity (4).  In 
the present study, rats with STZ-induced DM demonstrated increased myocardial 
oxidative stress as shown by increased NADPH oxidase subunit p22phox and gp91phox 
expression.  The NADPH oxidase enzyme is an important source of ROS in 
vascular cells such as smooth muscle and endothelial cells (32, 33).  F2 isoprostanes 
are a family of prostaglandin F2α isomers that are produced in vivo primarily from 
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oxidative modification of polyunsaturated fatty acids via a free radical-catalyzed 
mechanism.  PGF2α is a major F2 isoprostane and was shown to be a specific and 
sensitive index of oxidative stress in vivo (34, 35).  We demonstrated previously 
that cardiac PGF2α levels are markedly increased in rats with STZ-induced DM 
(20).   
 Long-term treatment with fluvastatin attenuated STZ-induced LV 
dysfunction in association with decreases in both cardiac PGF2α and NADPH 
oxidase subunit p22phox and gp91phox mRNA expression.  In situations involving 
weakened antioxidant defence, superoxide anion will scavenge NO and lower NO 
bioavailability, leading to increased ROS production and inflammation (36).  
Excess oxidative stress might interfere with the VEGF signaling in DM (37).  
Statins decrease free radical generation in the vascular wall and myocardium (16, 
38), while fluvastatin exerts potent antioxidant activities as a free radical 
scavenger—a property that is derived from its unique chemical structure (18, 39).  
Thus, in the present study, fluvastatin reduced cardiac oxidative stress in rats with 
DM, a finding consistent with that of an earlier study (20).     
Coronary vascularity 
 Endothelial NOS was found to be dysfunctional due to reduced 
bioavailability of tetrahydrobiopterin (BH4) (40), while VEGF was downregulated in 
animals with STZ-induced DM (11, 41).   The migratory and NO-releasing capacity 
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of endothelial progenitor cells (EPCs) was impaired by DM (11, 42).  Thus, 
angiogenic factors of VEGF and eNOS are downregulated, which in turn hampers 
vessel formation in ischemic tissues.   
 Statins promote angiogenesis in ischemic limbs of animals (14).  
Nitropravastatin, an NO-releasing pravastatin derivative, stimulated reparative 
neovascularization and improved the recovery from limb ischemia in mice with 
STZ-induced DM (43).  Statins facilitate the protein kinase Akt–eNOS interaction, 
promote eNOS activation/phosphorylation and NO-mediated angiogenesis, and 
mobilize EPCs from the bone marrow (17).    The pro-angiogenic effect of statin 
may be ascribed to the activation of phosphatidylinositol 3-kinase (PI3K) -Akt 
pathway, and NO up-regulates the VEGF gene expression through a PI3K-Akt 
pathway, followed by induction of several transcription factors, especially HIF-1α 
(44, 45). In the present study, fluvastatin-induced up-regulation of VEGF was 
parallel to fuluvastatin-induced changes in HIF-1α expression.  On the other 
hand, VEGF initiates the signaling cascades leading to NO production and 
angiogenesis (46).  Thus the full pathways of fluvastatin-induced improvement of 
capillary density in DM remain to be elucidated, but the fluvastatin-induced 
up-regulation of eNOS and activation of VEGF signaling mediated by HIF-1α 
might be involved.   
 Microvascular abnormalities in patients with DM may lead to reduced 
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perfusion and mismatch of myocardial supply and demand.  These microvascular 
changes may lead to ischemia in the absence of coronary atherosclerosis and 
contribute to adverse cardiovascular events in the DM patient (10, 47).  A 
non-atherogenic cardiomyopathy occurs in roughly 30% of all type 1 DM patients 
(29), and pharmacological interventions for restoring coronary microvascular 
abnormalities may inhibit developing diabetic cardiomyopathy and adverse 
cardiovascular events.  
Limitations 
 The present study had several limitations.  First, the beneficial effects of 
fluvastatin on diabetic cardiomyopathy might be a result, at least in part, of 
improved coronary microvasculature by reducing myocardial oxidative stress and 
eNOS and VEGF up-regulation, but other factors such as the statin-induced 
suppression of inflammation or free radical generation may also contribute to 
improved diabetic cardiomyopathy (38, 48, 49).  Fluvastatin up-regulated 
myocardial eNOS mRNA and its protein levels, but the phosphorylation of eNOS 
was not evaluated in the present study.  The phosphorylation of eNOS might be 
important in angiogenesis and vascular homeostasis.  Second, the correlation of 
myocardial capillary densities with eNOS or VEGF levels was not analysed because 
the animals that determined capillary densities were different from those for PCR 
or immunoblotting.  Third, we did not determine the dose-response effect of 
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fluvastatin for protection of STZ-induced cardiomyopathy.  In our previous studies, 
a 2-week treatment with fluvastatin (10 mg/kg/day) attenuated 
ischemia-reperfusion injury of non-diabetic rat heart (50), and this dose of 
fluvastatin reduced myocardial oxidative stress in rats with STZ-induced DM (20).  
Hayashidani et al. (51) reported that plasma concentration of fluvastatin in mice 
treated at the oral dose of 10 mg/kg/day was within the range of humans achieved 
after oral administration of its clinical doses (10 to 20 mg).  According to these 
studies, we performed the study in the present dose of fluvastatin.  Fluvastatin 
had dose-dependent free radical scavenging action in vitro (52), whereas low-dose 
statins were more effective than high-dose statins for augmenting collateral flow 
recovery in the ischemic limbs of ApoE-deficient mice (53).  The influence of low- or 
high-dose fluvastatin on diabetic cardiomyopathy remains to be elucidated.  
Finally, it remains unknown whether statins other than fluvastatin have similar 
beneficial effects on diabetic cardiomyopathy.  Van Linthout et al (48) showed that 
atorvastatin decreased intramyocardial inflammation and myocardial fibrosis, 
resulting in improved LV function in rats with DM, although they did not examine 
coronary vasculature.  Sata et al (53) reported that all statins including 
cerivastatin, pitavastatin, and fluvastatin augmented capillary formation in 
ischemic limbs of mice without DM.  Therefore, statins other than fluvastatin 
might have also promoted cardiac angiogenesis in animals with DM. 
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CONCLUSION 
 Long-term fluvastatin treatment attenuated cardiac dysfunction in rats 
with STZ-induced DM.  This beneficial effect of fluvastatin might have resulted, at 
least in part, from the attenuation of DM-induced deterioration within the coronary 
microvasculature in association with reduced cardiac oxidative stress.  The present 
results suggest that long-term treatment with statin might be beneficial to patients 
with diabetic cardiomyopathy.   
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